| Literature DB >> 28344882 |
Chuangzhong Deng1, Zaishang Li1, Shengjie Guo1, Peng Chen2, Xiaofeng Chen3, Qianghua Zhou1, Jieping Chen1, Xingsu Yu4, Xiaoliang Wu4, Wenjuan Ma4, Qiankun Xie4, Yunlin Ye1, Yonghong Li1, Zike Qin1, Zhuowei Liu1, Ranyi Liu5, Zhenfeng Zhang4, Kai Yao1, Hui Han1, Fangjian Zhou1.
Abstract
Despite its rare incidence worldwide, penile squamous cell carcinoma (PeSCC) still presents with significant morbidity and mortality due to the limited treatment options for advanced patients, especially those in developing countries. The program death-1 (PD-1)/PD-1 ligand (PD-L1) axis has been demonstrated to play an important role in tumor immune escape, and immunotherapies targeting this pathway have shown great success in certain cancer types. Here, we analyzed the expression pattern of PD-L1 in tumor cells and tumor-infiltrating lymphocytes (TILs) in PeSCC with a multi-center cohort. We found that the majority of PeSCCs (53.4%) were PD-L1-positive and that high PD-L1 expression in tumor cells was associated with a poor prognosis. Notably, PD-L1 expression in tumor cells was significantly associated with the extent of TILs and CD8+ TILs. Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) showed that PD-L1 was positively correlated with interferon-gamma (IFNγ) and CD8+ gene expression. Moreover, we defined the constitutive and inducible surface expression of PD-L1 in newly established primary PeSCC cell lines. Interestingly, two PeSCC cell lines had high intrinsic PD-L1 expression. Another cell line showed low PD-L1 expression, but the PD-L1 expression could be induced by IFNγ stimulation. Overall, our data showed that high PD-L1 expression in penile tumor cells indicated a poor prognosis. The upregulation of PD-L1 in PeSCC included both extrinsic and intrinsic mechanisms. These findings indicated that the PD-1/PD-L1 axis might be a potential therapeutic target for patients with penile squamous cell carcinoma.Entities:
Keywords: IFNγ; PD-L1; immunohistochemistry; penile cancer; penile cancer cell line; tumor-infiltrating lymphocytes
Year: 2016 PMID: 28344882 PMCID: PMC5353932 DOI: 10.1080/2162402X.2016.1269047
Source DB: PubMed Journal: Oncoimmunology ISSN: 2162-4011 Impact factor: 8.110